ABT-925 ANHYDROUS FREE BASE

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C20H27F3N6OS
Molecular Weight	456.528
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of ABT-925 ANHYDROUS FREE BASE

Structure Search

SMILES

CC(C)(C)C1=NC(=CC(=N1)C(F)(F)F)N2CCN(CCCSC3=NC=CC(=O)N3)CC2

InChI

InChIKey=KXVAICSRMHXLJN-UHFFFAOYSA-N

InChI=1S/C20H27F3N6OS/c1-19(2,3)17-25-14(20(21,22)23)13-15(26-17)29-10-8-28(9-11-29)7-4-12-31-18-24-6-5-16(30)27-18/h5-6,13H,4,7-12H2,1-3H3,(H,24,27,30)

HIDE SMILES / InChI

Molecular Formula	C20H27F3N6OS
Molecular Weight	456.528
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21346607 | https://adisinsight.springer.com/drugs/800012940

Abbott Laboratories was developing the selective dopamine D3 receptor antagonist, ABT-925 (formerly A 437203), for the treatment of schizophrenia. ABT-925 is a selective dopamine D₃ receptor antagonist with an approximately 100-fold higher in vitro affinity for dopamine D₃ versus D₂ receptors. ABT 925 was undergoing phase II clinical development for the treatment of schizophrenia. However, development was discontinued in December 2007.

Originator

Approval Year

PubMed

Title	Date	PubMed
A double-blind, randomized, placebo-controlled study of the dopamine D₃ receptor antagonist ABT-925 in patients with acute schizophrenia.	2011 Apr	21346607
Dopamine D₃ receptor antagonism--still a therapeutic option for the treatment of schizophrenia.	2013 Feb	23128852
Pharmacological targeting of dopamine D3 receptors: Possible clinical applications of selective drugs.	2015 Sep	26298833

Sample Use Guides

In Vivo Use Guide

Schizophrenia: One hundred fifty-five patients were assessed over a 6-week double-blind treatment period (placebo: n = 48; ABT-925 50 mg once daily [QD]: n = 53; ABT-925 150 mg QD: n = 54). No statistically significant treatment effect was observed with ABT-925 50 mg QD or 150 mg QD compared with placebo on primary or secondary efficacy end points. Pharmacokinetic parameter estimates increased with dose in a linear fashion. ABT-925 50 mg QD and 150 mg QD were generally well tolerated, with adverse event profiles similar to that of placebo.

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Mon Mar 31 21:11:34 GMT 2025` Edited by `admin` on `Mon Mar 31 21:11:34 GMT 2025`
Record UNII	E6CKI5C54O
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ABT-925 ANHYDROUS FREE BASE

Common Name

English

A 37203

Preferred Name

English

ABT-925 FREE BASE

Common Name

English

LU-201640

Code

English

LU 201640

Code

English

4(1H)-PYRIMIDINONE, 2-((3-(4-(2-(1,1-DIMETHYLETHYL)-6-(TRIFLUOROMETHYL)-4-PYRIMIDINYL)-1-PIPERAZINYL)PROPYL)THIO)-

Systematic Name

English

4(3H)-PYRIMIDINONE, 2-((3-(4-(2-(1,1-DIMETHYLETHYL)-6-(TRIFLUOROMETHYL)-4-PYRIMIDINYL)-1-PIPERAZINYL)PROPYL)THIO)-

Systematic Name

English

A-37203

Code

English

Code System Code Type Description

PUBCHEM

9916104